grant
Project 1: Understanding population-based disparities in treatment-associated hepatotoxicity during ALL therapy
Organization BAYLOR COLLEGE OF MEDICINELocation HOUSTON, UNITED STATESPosted 23 Sept 2025Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY20250-11 years oldASP-1AcuteAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Lymphoid LeukemiaAcute leukemiaAddressAdolescentAdolescent YouthAdolescent and Young AdultAdult Acute Lymphoblastic LeukemiaAdult Acute Lymphocytic LeukemiaAdult Acute Lymphogenous LeukemiaAdult Acute Lymphoid LeukemiaAdverse ExperienceAdverse eventAffectAsparaginase IIAsparagine DeaminaseBiologicalBiological MarkersBlood PlasmaCaliforniaCancer TreatmentCausalityCephalinsChildChild YouthChildhoodChildhood ALLChildhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphocytic LeukemiaChildhood Acute Lymphogenous LeukemiaChildhood Acute Lymphoid LeukemiaChildren (0-21)Choline GlycerophospholipidsCholine PhosphoglyceridesClinicalColaspaseCross-Product RatioDataDiagnosisDietDiseaseDisorderDisparitiesDisparityDose LimitingDysfunctionDyslipidemiasElsparEnrollmentEpidemiologyEthanolamine PhosphoglyceridesEthanolamineglycerophospholipidsEtiologyFrequenciesFunctional disorderGenesGeneticGenetic DiversityGenetic VariationGenomicsGoalsHepatotoxic effectHepatotoxicityHereditaryIPO-BIncidenceIndophenol Oxidase BInduction TherapyInheritedInstitutionInterventionInvestigationInvestigatorsKidrolaseKnock-outKnockoutL asparagine amidohydrolaseL-ASPL-AsparaginaseL1 Lymphocytic LeukemiaLatinoLatino PopulationLatino groupLatino individualLatino peopleLatinosLcf-ASPLeannessLecithinLipidsLiver ToxicityLymphoblastic Leukemia, Acute, L1MNSODMalignant Neoplasm TherapyMalignant Neoplasm TreatmentManganese Superoxide DismutaseMitochondrial Superoxide DismutaseMn Superoxide DismutaseMn-SODModelingMolecular EpidemiologyNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNewly DiagnosedNon obeseNonobeseO-(1-beta-acyl-2-acyl-sn-glycero-3-phospho)-ethanolamineObesityOdds RatioOutcomeOxidantsOxidative StressOxidizing AgentsPathway interactionsPatientsPediatric ALLPediatric Acute Lymphoblastic LeukemiaPediatric Acute Lymphocytic LeukemiaPediatric Acute Lymphogenous LeukemiaPediatric Acute Lymphoid LeukemiaPediatric OncologyPediatric cohortPerformancePhasePhosphatidylcholinesPhosphatidylethanolaminePhysiopathologyPlasmaPlasma SerumPopulationPrecursor Cell Lymphoblastic LeukemiaPrecursor Lymphoblastic LeukemiaPrediction of Response to TherapyPredispositionPredisposition geneRandomization trialRelative OddsResearchResearch PersonnelResearch ResourcesResearchersResourcesReticuloendothelial System, Serum, PlasmaRiskRisk FactorsRisk RatioRoleSOD2SOD2 geneSamplingSerasaSuperoxide Dismutase 2Supportive TherapySupportive careSurvival RateSusceptibilitySusceptibility GeneTestingTexasTherapeuticThinnessToxic effectToxic effect on liver cellsToxicitiesTreatment EfficacyTreatment ProtocolsTreatment RegimenTreatment ScheduleTreatment outcomeTreatment-related toxicityValidationacute lymphatic leukemiaacute lymphogenous leukemiaacute lymphomatic leukemiaadiposityadult ALLadverse consequenceadverse outcomeanti-cancer therapyasparaginasebio-markersbiologicbiologic markerbiomarkercancer therapycancer-directed therapycausationchemotherapychild patientsclinical riskcohortcorpulencecurative interventioncurative therapeuticcurative therapycurative treatmentsdietsdisease causationdisparities in treatmentdisparity in ethnicelectron acceptorenrollepidemiologicepidemiologicalessential phospholipidsethnic based disparityethnic disadvantageethnic disparityethnic inequalityethnic inequityethnicity disparityexperiencefat metabolismgenomic datagenomic datasethepatic toxicityhepatoxicityhigh riskimprovedimproved outcomeinduction therapiesinequality in treatmentinfant ALLinnovateinnovationinnovativeinsightintervention efficacyjuvenilejuvenile humankidsleukemia relapseleukemia treatmentleukemic therapylipid metabolismlipidomicsliver functionmedical collegemedical schoolsmetabolism measurementmetabolomicsmetabonomicsmouse modelmurine modelnovelparticipant enrollmentpathophysiologypathwaypatient enrollmentpatient populationpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespediatricpediatric patientspopulation basedpredict therapeutic responsepredict therapy responsepredisposing geneprematureprematurityprospectiverandomized trialrecurrent leukemiarisk stratificationschool of medicinescreeningscreeningssite targeted deliverysocial rolestratify risksusceptibility allelesusceptibility locussusceptibility varianttargeted deliverytherapeutic efficacytherapeutic toxicitytherapy associated toxicitytherapy efficacytherapy predictiontherapy related toxicitytherapy toxicitytranslational opportunitiestranslational potentialtreatment disparitytreatment inequalitytreatment inequitytreatment predictiontreatment response predictiontreatment risktreatment toxicitytreatment-associated toxicityvalidationsyoungster
Description preview
Project 1: Understanding population-based disparities in treatment-associated hepatotoxicity during ALL therapy
Project Summary
This proposal seeks to integrate clinical, demographic, lipidomic, and genomic data to advance our
understanding of disparities in treatment-related hepatoxicity (TAH) during induction therapy for pediatric acute…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click